News Health Systems

Senators Among Those Questioning Cost of Drug to Cure Hepatitis C

Martha Kempner

Sovaldi is a breakthrough drug that can cure 90 percent of chronic Hepatitis C infections, but industry experts and lawmakers are questioning whether it should cost $84,000 per person.

Sovaldi, a drug to cure Hepatitis C, made headlines when it was approved in December as a breakthrough in treatment for this chronic and potentially fatal liver disease. This week it is making headlines again, as the manufacturer announced sales of $3.5 billion for the second quarter alone, and many people, including two U.S. Senators, are questioning whether even a miracle cure should have such a high price tag.

Hepatitis C is a contagious liver disease that is spread primarily through contact with another person’s infected blood. Though it can be spread sexually, the risk of this is low. Most often, people become infected with Hepatitis C by sharing needles to inject drugs. The virus can also be transmitted from an infected mother to her child during pregnancy and childbirth. Though some cases of Hepatitis C are acute, meaning they pass quickly, most people who get the virus will have a chronic or continuing infection. Chronic Hepatitis C can lead to long-term health problems, liver failure, and liver cancer.  It is the leading cause of cirrhosis and liver cancer and the most common reason for liver transplants in the United States. The Centers for Disease Control and Prevention estimates that there are 3.2 million people in the United States living with Hepatitis C, and about 15,000 people die from it each year.

Sovaldi is definitely a game-changer. Before it was approved, patients relied on drugs that had numerous side effects and a cure rate of about 50 percent. In clinical trials, Sovaldi, which is taken as one pill a day for 12 weeks, had few side effects and cured nine out of ten patients. The problem, however, is that each pill costs $1,000, meaning the entire course of treatment comes at a price of $84,000.

Gilead, the manufacturer of the Sovaldi, is defending its price point by highlighting its cure rate, its research-and-development costs, and the other costly treatments—such as liver transplants—that Hepatitis C patients who take the drug will no longer need. But these arguments are not convincing to many in the health-care world, who say that with estimated 2014 sales of $10 billion, Gilead—which bought the start-up company that invented Sovaldi—will make back its investment many times over; Sovaldi is now one of the highest-selling prescription drugs of all time. Others note that costly treatments like liver transplants were not inevitable even without this new cure, as only about 1 or 2 percent of individuals with Hepatitis C ever get to that point.

Appreciate our work?

Vote now! And help Rewire earn a bigger grant from CREDO:


In their letter to the manufacturer, Sens. Ron Wyden (D-OR) and Chuck Grassley (R-IA) note that before Gilead acquired the drug’s developer, the projected price for a 12-week course of treatment was $36,000 ($48,000 less than the current price tag). The letter reads in part, “It is unclear how Gilead set the price for Sovaldi. That price appears to be higher than expected given the cost of development and production and the steep discounts offered in other countries.” The letter asks the company to explain the price and requests that information within the next two months. Gilead has said it will comply with the request.

In the meantime, industry analysts and insurers have weighed in, suggesting that this drug alone could cripple the system by which we pay for health care, ruin all attempts to reign in related costs, and cause insurance premiums to rise for everyone in the United States. One estimate, included in the lawmaker’s letter, suggested that the drug would cost Medicare Part D, the drug benefit program for senior citizens, $6.5 billion in the next year or so, which would lead to an 8 percent increase in premiums. Another estimate, by Express Scripts, the largest pharmacy benefit manager in the nation, set the cost to states at $55 billion to treat all Medicaid patients and prison inmates and called the drug “a tax on all Americans.” Executives at CVS Caremark, the nation’s second largest pharmacy benefit manager, wrote a commentary for the Journal of the American Medical Association, in which they argued that treating Hepatitis C patients would add $200 to $300 to every American’s premiums over the next five years.

The New York Times, however, points out that all of these estimates may be inflated because they assume that all three million individual with Hepatitis C will seek Sovaldi immediately. The Times notes that many of these people don’t know they are infected, and others have no symptoms so would likely not seek a cure right away. Moreover, it points out that the health-care system couldn’t accommodate treatment for everyone right away, so the costs would ultimately be spread out over a number of years.

Gilead also makes the HIV-prevention drug Truvada, and on Wednesday the Food and Drug Administration approved the company’s new drug, Zydelig, which is designed to treat three kinds of blood cancer.

News Sexual Health

Company Doesn’t Keep Promise to Lower Price of Drug Used By AIDS Patients

Martha Kempner

Pharmaceutical company Turing did not quite follow through on its promise of a "modest" price drop for a drug to treat an infection that can be life-threatening in those with HIV or AIDS. Competitors have decided to offer a $1 alternative.

Turing, a small pharmaceutical company, was caught in a swirl of negative publicity this fall when the New York Times announced that Turing had raised by almost 5,000 percent the price of an old drug used to treat an infection that can be life-threatening in those with HIV or AIDS or with otherwise compromised immune systems. The company’s founder and CEO promised at least a “modest” reduction in price, but did not quite follow through, announcing a discounting scheme instead.

Now, two companies in the pharmaceutical industry have declared that they will work together to provide an alternative drug for just $1 dollar a pill.

Turing spent $55 million dollars this summer for the right to produce and distribute Daraprim, a drug approved by the Food and Drug Administration (FDA) in 1952 to treat toxoplasmosis, as Rewire reported. This parasitic infection can come from eating undercooked meat or unwashed fruits and vegetables, or from cleaning out the litter box of an infected cat.

The parasite is common and most people never get symptoms, but it can be very dangerous to pregnant women and those with compromised immune systems, such as the elderly, infants, certain cancer patients, and people with HIV or AIDS.

Appreciate our work?

Vote now! And help Rewire earn a bigger grant from CREDO:


When Turing acquired Daraprim, it cost either $13.50 or $18 per pill (Turing’s CEO disputed reports that used the lower number). Regardless, the price hike—to $750 per pill—was alarming to patients and providers. A standard, two-week course of the medication went from costing $1,130 to $63,000. Some patients with compromised immune systems need to take Daraprim daily.

For them, the increase meant the drug would cost $634,500 per year.

Turing’s CEO, Martin Shkreli, defended the price increase, saying that his company needed to raise the price to continue making the drug and that it would funnel some profits into researching newer, better drugs to fight toxoplasmosis. But experts questioned why that was necessary as Daraprim still worked just fine.

In a late September interview, Shkreli said his company would lower the price of the drug but did not say by how much. He later said that the public could expect an announcement of modest decrease in price by the end of December.

What was ultimately announced, however, was somewhat different. Instead of lowering the list price, the company created a program to provide the pills to hospital at a 50 percent discount and promised to make smaller bottles so hospitals could afford to keep it in stock. Turing also promised to provide free sample starter packs to “ensure physicians treating patients in the community have free and immediate access to start therapy in emergency situations.”

The company vowed to participate in programs that make drugs more affordable to low-income people who benefit from Medicaid, the Section 340B program, and Patient Services, Inc. Turing said it would provide the drug free of charge to qualified patients with demonstrated income at or below 500 percent of the federal poverty level.

In its press release, the company tried to explain why it made these changes rather than a simple price reduction: “Drug pricing is one of the most complex parts of the healthcare industry. A drug’s list price is not the primary factor in determining patient affordability and access. A reduction in Daraprim’s list price would not translate into a benefit for patients.”

All of this, however, may become irrelevant because two companies have jumped in to provide an alternative. Drug maker Imprimis Pharmaceuticals has said it will create a compound of two drugs it already makes—pyrimethamine and leucovorin—that together can treat toxoplasmosis. Express Scripts, the largest pharmacy benefits management company in the country, has said that it will offer this compound to its patients for $1 per pill.

The companies have also announced an educational campaign to ensure that providers are aware of this low-cost alternative.

“We are pleased to partner with Express Scripts to take positive action to counterbalance companies like Turing and others in order to address the growing drug pricing crisis in America,” Mark Baum, the CEO of Imprimis, said in a statement.

In the meantime, Shkreli has been called to appear in front of Senate subcommittee on December 9 for a hearing on drug pricing. He told Business Insider, however, that he was unlikely to participate and pointed out that the committee doesn’t have subpoena power: “When my lawyers tell me I absolutely have to go, I’ll go,” he said.

News Health Systems

HIV Drug Price Increase Brings ‘Price Gouging’ to the Forefront

Martha Kempner

Reports that a drug that treats toxoplasmosis went from $13.50 to $750 per pill caused outrage among medical experts, politicians, and the public.

Pharmaceutical company Turing came under fire last week after the New York Times reported Turing had raised by about 5,000 percent the price of an old drug used to treat an infection that can be life-threatening in those with HIV or AIDS or with otherwise compromised immune systems.

The founder and CEO of the company, Martin Shkreli, initially defended its decision by saying Turing needed to make the drug profitable and planned to use the profits to make a newer, better drug. After being vilified in the press, however, Shkreli said on September 23 that Turing would lower the cost of Daraprim, though he did not say by how much. The controversy gave both medical professionals and politicians an opportunity to discuss the rising prices for drugs that treat myriad conditions.

Daraprim was approved by the Food and Drug Administration (FDA) in 1953 to treat toxoplasmosis, a parasitic infection that can come from eating undercooked meat or unwashed fruits and vegetables. It can also be contracted from cat feces when cleaning litter boxes. The parasite is common and most people never get symptoms, but it can be very dangerous to pregnant women and those with compromised immune systems, such as the elderly, infants, certain cancer patients, and people with HIV or AIDS.

The Centers for Disease Control and Prevention (CDC) estimates that about 4,400 people are hospitalized with the infection and more than 300 die each year. Most people who get sick from toxoplasmosis can be cured with a six-week dose of Daraprim. Those who are immunosuppressed, however, may have to take the drug continually.

Appreciate our work?

Vote now! And help Rewire earn a bigger grant from CREDO:


Not long ago, Daraprim cost about $1 per pill. But after GlaxoSmithKline sold the drug in 2010, its price has steadily increased. That year there were about 12,700 outpatient prescriptions for total sales of $667,000. In 2014, however, the number of outpatient prescriptions for the drug dropped to 8,821, but sales of the drug totaled $9.9 million.

There is some disagreement over the exact price of the drug in August when it was sold to Turing. Most reports say it cost about $13.50 per pill, but Shkreli told the Washington Post that each pill was $18 at the time. Either way, the price hike was alarming as Turing began to sell the drug for $750 per pill; an increase of at least 4,000 percent.

This meant that the standard six-week, two-pill-a-day course of treatment went from $1,130 to $63,000. For patients over 132 pounds who have to stay on Daraprim, the drug could cost as much as $634,500 every year.

The medical community called this move unconscionable and pointed out that making the drug so expensive might mean hospitals could not keep it in stock, which would, at the very least, delay treatment for some patients. The Infectious Diseases Society of America and the HIV Medicine Association sent a joint letter to Turing calling the move “unjustifiable for a medically vulnerable patient population” and “unsustainable for the health care system.”

Shkreli defended his company’s price hike saying that the previous manufacturer was practically giving the drug away and that his company couldn’t afford to do that. He argued that the drug is so rarely used that the new price would not impact the health-care system and promised that Turing would put a lot of its profits into researching newer and better drugs to treat toxoplasmosis. He told the Los Angeles Times: “We’re not going to take this money and put it in our pocket or pay ourselves a dividend. We’re not going to stop until we’ve eliminated toxoplasmosis.”

But this rationale was not satisfactory, as research into toxoplasmosis does not appear necessary. Dr. Carlos del Rio, an HIV and AIDS specialist at Emory University, told NBC News: “This is a drug that has no major side effects … it’s usually very well tolerated. It’s not a patient population that is clamoring for a better drug.”

Politicians got in on the outrage. Democratic Presidential candidate Hillary Clinton called the move “price gouging” and “outrageous” and used the story as a hook for releasing her drug pricing plan. Sen. Bernie Sanders (I-VT), who is also vying to be the Democratic candidate for president, and Rep. Elijah Cummings (D-MD) announced that they were requesting information from Turning on the “astronomical price increase.”

The two have spearheaded congressional investigations into drug prices. “The enormous, overnight price increase for Daraprim is just the latest in a long list of skyrocketing price increases for certain critical medications,” Sanders and Cummings said in a statement. “Americans should not have to live in fear that they will die or go bankrupt because they cannot afford to take the life-saving medication they need.”

There are many other examples of companies raising drug prices for no apparent reason other than bolstering the profit margin.

Doxycycline, a common antibiotic used to treat everything from urinary tract infections and chlamydia to Lyme disease and anthrax exposure, went from $20 a bottle in 2013 to $1,849 in 2014. When Rodelis Therapeutics acquired the rights to manufacture Cycloserine, which treats multidrug-resistant tuberculosis, the cost went from $500 a bottle to $10,800. When Valeant Pharmaceuticals bought two heart medications from Marathon Pharmaceuticals, it raised the price of one by 212 percent and the other by 525 percent. This was particularly startling because Marathon had already quintupled the price of the drugs when it acquired them.

Those price hikes are part of the congressional investigations. Those increases did not, however, capture the public’s attention as much the story of Daraprim. Much of the anger seemed to be directed as Shkreli, a 32-year-old former hedge fund manager, who initially said he would not consider lowering the price and called a journalist who questioned his decision “a moron” on Twitter.

Journalists pointed out that this was not the first time Shkreli drastically raised prices on a medication. His former company, Retrophin, bought the rights to a drug called Thiola, which can prevent or reduce the frequency of kidney stones in some patients who are prone to them. When Retrophin acquired the drug, it raised the price from $1.50 per pill to more than $30, meaning that annual treatment for patients who have to stay on the drug went from $2,700 to $54,750.

Urologist Benjamin Davies of the University of Pittsburgh accused Shkreli of having “grabbed an old drug, made no changes to it at all, and hiked the price exorbitantly.”

Shkreli was ousted from and is currently being sued by Retrophin for unrelated issues.

The public pressure seems to have forced Shkreli to reconsider.

“Yes it is absolutely a reaction—there were mistakes made with respect to helping people understand why we took this action, I think that it makes sense to lower the price in response to the anger that was felt by people,” he told NBC News.


Vote for Rewire and Help Us Earn Money

Rewire is in the running for a CREDO Mobile grant. More votes for Rewire means more CREDO grant money to support our work. Please take a few seconds to help us out!


Thank you for supporting our work!